Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Researchers ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...

That’s where GlucoBoost GLP-1 Booster comes into play. This innovative supplement has garnered attention for its natural approach to weight loss, appealing to those who prefer avoiding synthetic ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class ...

Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 25, 2024 (HealthDay News) -- As the popularity of GLP-1 meds like Wegovy and ...

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...

But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound, more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a ...

A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding they are associated with a high cost of care with little benefit beyond ...

These findings are part of Prime's ongoing GLP-1 research, including its most recent study, which showed 85% of individuals taking GLP-1 drugs for weight loss no longer took the drug after two years.

If employees are asking about GLP-1 coverage — in pursuit of general weight loss, not just to treat diabetes — HR may need a plan. At a recent Digital Health New York session titled “The ...

An increasing number of states are considering adding coverage for GLP-1 weight loss medications for their Medicaid enrollees. Eli Lilly's (NYSE:LLY) Zepbound (tirzepatide) and Novo Nordisk's (NVO ...